Copy

M2Bio Sciences (OTC: $WUHN) Launches Mental Illness Drug Discovery Company Neurai Life Sciences.

Cherished investors and subscribers,

M2Bio Sciences, Inc. (OTC: $WUHN) is excited to announce the launch of Neurai Life Sciences. Neurai Life Sciences is a pre- and clinical-stage biotechnology company focusing on the drug discovery and development of next-generation therapies treating mental health disorders.

The company will lead the industry in artificial intelligence-driven target discovery, innovative and sustainable small molecule chemistry, and inclusive clinical development in the pursuit of novel therapeutics for major depressive disorder, anxiety disorders, and addiction.

Neurai Life Sciences is primed to realize the infinite potential of targeted therapeutics within the brain serotonin receptor-mediated signaling pathways.

With the goal of hiring the best international talent, Neurai Life Sciences has recruited Riyad Domingo Ph.D. as Chief Executive Officer. Dr. Domingo is the current Harvard South Africa Fellow for 2021-2022 and holds a doctorate in Medical Biochemistry with a focus on drug discovery and development from the Institute of Infectious Diseases and Molecular Medicine at the University of Cape Town.

At this time, Neurai Life Sciences is a private company and 100% owned by Wuhan General, Inc. / M2Bio Sciences (OTC: $WUHN). 

Neurai Life Sciences will be conducting a capital raise to fund initial preclinical research, development, and validation of select drug candidates.

 ➡ Read the full Press Release here. ⬅


Sincerely,


Jeff Robinson and Dr. Anna Morera Leralta

Twitter Twitter
LinkedIn LinkedIn
Facebook Facebook
Instagram Instagram
 
 

                     M2Bio Sciences, Inc.  |  12 Park Road Place, 9 Park Road, Gardens    |  Cape Town 8001, South Africa

 

Copyright © |2021| |OTCMKTS: WUHN| or its affiliates. All rights reserved. M2bio Sciences, Dr. AnnaRx, Medspresso, the logo, and all other related logos are trademarks of M2Bio Sciences, Inc. or its affiliates.

You've received this email because you opted in via our website or have shown an interest in the past. If you wish to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

 

Email Marketing Powered by Mailchimp